Barclays Lowers Humana (NYSE:HUM) Price Target to $250.00

Humana (NYSE:HUM) had its target price reduced by equities researchers at Barclays from $364.00 to $250.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s target price would suggest a potential downside of 3.13% from the company’s current price.

HUM has been the topic of several other reports. UBS Group cut their target price on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a research note on Tuesday. TD Cowen downgraded Humana from a “buy” rating to a “hold” rating and dropped their price target for the stock from $402.00 to $261.00 in a research note on Monday, October 7th. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price target on shares of Humana in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada dropped their price target on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $315.33.

Humana Stock Performance

Shares of HUM opened at $258.07 on Thursday. The business’s fifty day simple moving average is $324.76 and its two-hundred day simple moving average is $340.20. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana has a 12 month low of $213.31 and a 12 month high of $530.54. The company has a market cap of $31.07 billion, a price-to-earnings ratio of 18.41, a P/E/G ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the business posted $8.94 EPS. The company’s revenue was up 10.4% compared to the same quarter last year. Research analysts anticipate that Humana will post 16.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Willner & Heller LLC raised its holdings in Humana by 17.2% during the third quarter. Willner & Heller LLC now owns 1,562 shares of the insurance provider’s stock valued at $495,000 after acquiring an additional 229 shares during the period. Koshinski Asset Management Inc. raised its holdings in Humana by 32.4% during the third quarter. Koshinski Asset Management Inc. now owns 1,499 shares of the insurance provider’s stock valued at $475,000 after acquiring an additional 367 shares during the period. Exchange Traded Concepts LLC bought a new stake in Humana during the third quarter valued at about $348,000. Gateway Investment Advisers LLC grew its position in shares of Humana by 6.1% during the third quarter. Gateway Investment Advisers LLC now owns 3,112 shares of the insurance provider’s stock valued at $986,000 after purchasing an additional 180 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Humana by 49.6% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 4,827 shares of the insurance provider’s stock valued at $1,532,000 after purchasing an additional 1,600 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.